Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H17N5O |
Molecular Weight | 307.3498 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)N1N=NN=C1CC2=CC=C(C=C2)C3=CC=CC=C3
InChI
InChIKey=GZNIYOXWFCDBBJ-UHFFFAOYSA-N
InChI=1S/C17H17N5O/c1-21(2)17(23)22-16(18-19-20-22)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
Molecular Formula | C17H17N5O |
Molecular Weight | 307.3498 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21764305 |
12.0 nM [IC50] | ||
Target ID: CHEMBL4191 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19583260 |
54.4 nM [IC50] |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:20:50 GMT 2023
by
admin
on
Sat Dec 16 10:20:50 GMT 2023
|
Record UNII |
2WBU91OKM7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-LY-2183240
Created by
admin on Sat Dec 16 10:20:50 GMT 2023 , Edited by admin on Sat Dec 16 10:20:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LY-2183240
Created by
admin on Sat Dec 16 10:20:50 GMT 2023 , Edited by admin on Sat Dec 16 10:20:50 GMT 2023
|
PRIMARY | LY-2183240 is a drug which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. This leads to markedly elevated anandamide levels in the brain, and LY-2183240 has been shown to produce both analgesic and anxiolytic effects in animal models. While LY-2183240 is a potent inhibitor of FAAH, it has relatively poor selectivity and also inhibits several other enzyme side targets. Consequently, it was never developed for clinical use, though it remains widely used in research, and has also been sold as a designer drug. | ||
|
874902-19-9
Created by
admin on Sat Dec 16 10:20:50 GMT 2023 , Edited by admin on Sat Dec 16 10:20:50 GMT 2023
|
PRIMARY | |||
|
DTXSID001024706
Created by
admin on Sat Dec 16 10:20:50 GMT 2023 , Edited by admin on Sat Dec 16 10:20:50 GMT 2023
|
PRIMARY | |||
|
11507802
Created by
admin on Sat Dec 16 10:20:50 GMT 2023 , Edited by admin on Sat Dec 16 10:20:50 GMT 2023
|
PRIMARY | |||
|
2WBU91OKM7
Created by
admin on Sat Dec 16 10:20:50 GMT 2023 , Edited by admin on Sat Dec 16 10:20:50 GMT 2023
|
PRIMARY | |||
|
LY-2183240
Created by
admin on Sat Dec 16 10:20:50 GMT 2023 , Edited by admin on Sat Dec 16 10:20:50 GMT 2023
|
PRIMARY | Novel and highly potent blocker of anandamide uptake (IC50 = 270 pM). Inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). Following i.p. administration in rats, increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |